Peter Lucks

Establishing Targeted Lung Denervation as a novel interventional therapy for COPD patients in Germany, Austria and Switzerland. - building a market access strategy; specific focus on reimbursement in Germany, KOL management and Centers of Excellence - Clinical procedure support and personnel training in the bronchoscopy suite - Reporting to the Global SVP

- Full responsibility for sales activities in Germany - Managing a team of 10

- Providing Sales and Clinical expertise around the neurovascular portfolio to the sales team, leveraging my extensive interventional experience.

- Delivered 90% YoY growth in Embotrap sales in Western Germany - Developed relationships to top tier KOLs in the neurovascular space - Worked closely with R&D team to establish positive brand perception in the market

- Regional sales management covering Southern Germany - Four direct reports - Revenue responsibility 13m€

Starting Sales of the Next Generation of Bioresorbable Scaffolds - DESolve - First Account Manager in Germany to build up sales in Western Germany from 0€ to 1m€ within two years - Created market development program to be rolled-out internationally

- Therapy development of the novel interventional treatment of refractory hypertension.

- Grew business by 3% in shrinking market two years in a row - Certified trans-regional trainer for intravascular ultrasound (inbound and outbound training) - First or second in three sales-relevant incentive programs

- Operational responsibility for Regulatory and Quality matters in the DACH region for all business units

University of Massachsetts, Boston Harvard Medical School, Boston